RFliC prolongs allograft survival in association with the activation of recipient Tregs in a TLR5-dependent manner.

ABSTRACT: Allorejection remains an obstacle for successful organ transplantation. Although different types of immunosuppressive agents are effective for controlling rejection and prolonging graft survival, drug treatment is limited because of side effects and toxicity. Therefore, it is necessary and urgent to identify new candidate drugs for inducing allotolerance. Recently, it has been reported that bacterial flagellin induces the immunosuppressive activity of regulatory T cells (Tregs) in humans in vitro. In the present study, we analyzed the effects of recombinant flagellin (rFliC) on allograft survival and explored the underlying mechanisms associated with the activation of recipient Tregs in a murine skin allotransplantation model. The results showed that rFliC administration (3 mg/kg, once per

SUBMITTER: Hao J 

PROVIDER: S-EPMC4003372 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature